Akebia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	232.4	236.2	160.18	194.62	292.48	211.65
Revenue Growth (YoY)	25.69%	47.46%	-17.70%	-33.46%	38.19%	-28.17%
Cost of Revenue	44.13	39.46	63.18	74.15	85.57	150.67
Gross Profit	188.28	196.73	97	120.47	206.92	60.98
Selling, General & Admin	112.17	107.48	106.55	100.23	138.6	174.14
Research & Development	67.41	62.36	37.65	63.08	129.99	147.85
Other Operating Expenses	3.4	3.4	3.28	3.42	19.11	3.49
Total Operating Expenses	182.99	173.24	147.48	166.73	287.7	325.48
Operating Income	5.29	23.5	-50.47	-46.26	-80.78	-264.5
Interest Expense	-21.1	-24.18	-18.19	-6.03	-15.69	-
Other Non-Operating Income (Expense)	-7.78	-3.04	-0.75	0.36	2.24	-17.52
Total Non-Operating Income (Expense)	-28.88	-27.22	-18.94	-5.67	-13.45	-17.52
Pretax Income	-18.76	-3.72	-69.41	-51.93	-94.23	-282.02
Provision for Income Taxes	-	1.62	-	-	-	-
Net Income	-8.27	-5.35	-69.41	-51.93	-94.23	-282.02
Net Income to Common	-8.27	-5.35	-69.41	-51.93	-94.23	-282.02
Shares Outstanding (Basic)	265	257	211	187	183	166
Shares Outstanding (Diluted)	269	257	211	187	183	166
Shares Change (YoY)	22.44%	21.91%	12.53%	2.56%	10.14%	19.85%
EPS (Basic)	-0.08	-0.02	-0.33	-0.28	-0.52	-1.70
EPS (Diluted)	-0.08	-0.02	-0.33	-0.28	-0.52	-1.70
Free Cash Flow	60.04	67.7	-40.69	-23.38	-73.27	-253.02
Free Cash Flow Growth	-11.32%	-	-	-	-	-
Free Cash Flow Per Share	0.22	0.26	-0.19	-0.12	-0.40	-1.52
Gross Margin	81.01%	83.29%	60.56%	61.90%	70.74%	28.81%
Operating Margin	2.28%	9.95%	-31.51%	-23.77%	-27.62%	-124.97%
Profit Margin	-3.56%	-2.26%	-43.33%	-26.68%	-32.22%	-133.25%
FCF Margin	25.83%	28.66%	-25.40%	-12.02%	-25.05%	-119.55%
EBITDA	6.57	24.77	-12.97	-8.63	-43.08	-226.53
EBITDA Margin	2.83%	10.49%	-8.10%	-4.43%	-14.73%	-107.03%
EBIT	5.29	23.5	-50.47	-46.26	-80.78	-264.5
EBIT Margin	2.28%	9.95%	-31.51%	-23.77%	-27.62%	-124.97%
Effective Tax Rate	-	-43.64%	0.00%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q